Clinical Trial

CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 5, 2026 (before its estimated June 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-03-25 -> 2026-06-25 2026-05-06
Trial Details
NCT Number NCT06696170
Lead Sponsor Pulse Biosciences, Inc.
Conditions Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia
Enrollment 60 participants
Start Date 2024-07-25
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-07-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-05